Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

AbbVie’s Rinvoq supports clinical remission in Phase 3 Crohn’s disease study

By Brian Buntz | May 11, 2022

AbbVieAbbVie (NYSE:ABBV) has revealed positive topline results from the U-ENDURE Phase 3 study investigating 15- and 30-mg doses of Rinvoq (upadacitinib) in adults with moderate to severe Crohn’s disease.

Recipients who received either dose met the co-primary endpoints of endoscopic response and clinical remission, AbbVie announced. More than one-third (36%) of participants who received 15 mg of upadacitinib achieved clinical remission at week 52. A total of 46% of those receiving the 30-mg dose achieved the same benchmark, compared with 14% of placebo recipients.

Subjects also achieved the secondary endpoint of endoscopic remission at 52 weeks compared to placebo.

Study participants were poor candidates for conventional or biologic therapy.

The study defined clinical remission using the Crohn’s Disease Activity Index (CDAI) or by stool frequency and abdominal pain score (SF/AP).

Rinvoq first won FDA approval in 2019 for rheumatoid arthritis. Indications followed for psoriatic arthritis, atopic dermatitis, ulcerative colitis and ankylosing spondylitis.

AbbVie noted that it would include data from the U-ENDURE study as well as the U-EXCEED and U-EXCEL Phase 3 studies in future regulatory submissions.

“We are deeply committed to supporting Crohn’s disease patients who continue to live with challenging symptoms that impact their daily lives,” said Dr. Thomas Hudson, senior vice president, research and development, chief scientific officer at AbbVie, in a statement. “These results represent important progress as we work to bring new treatment options to patients with inflammatory bowel disease.”

The company is studying the use of Rinvoq for several other immune-mediated diseases.

International sales of Rinvoq in 2021 were $1.651 billion.

ABBV shares were mostly flat today, ending up at $151.96.

 


Filed Under: Gastroenterology
Tagged With: AbbVie, Crohn's disease, immune-mediated diseases, Rinvoq
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

First Wave BioPharma
First Wave BioPharma stock tanks after announcing COVID-19 therapy trial data
Pfizer
Pfizer unveils promising data from Phase 3 study of etrasimod in ulcerative colitis
Janssen
Janssen’s pathway strategy shows promise for people with inflammatory bowel disease
Boehringer Ingelheim/AbbVie
FDA lengths review of Skyrizi for Crohn’s

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50